Boston Scientific Corp (BSX) Buy, Sell or Hold

Boston Scientific Corp (BSX)

45.39

+0.34 (0.75%)

as of Oct 20, 2026, 5:45:00 pm Market Open.

102 watching

BUY

They minimally invasive surgical devices, particularly in cardio-vascular, plus medical services. Last year, shares rallied 55% and is up 6% so far this year, thanks to JNJ pausing a competing device. He expects double-digit growth across the entire business, which is rare for pharma.

Wealthica Track your Stocks in your Watch List

BUY

It just reported a strong revenue beat with over 14.7% organic growth and raise their full-year forecast in earnings and revenues. Was down 1% today in the sell-off, but still worth buying.

BUY

BDX vs. TMO

Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.

PAST TOP PICK

(A Top Pick Dec 28/22, Up 27%)

Still owns shares. Venture capital fund in health care business. One of most successful funds in biotech. Expecting consistent gains going forward.

HOLD

Above FMV of $40 by 22%. Growth is fairly nice. He thinks it will hold fairly well. A bouncy kind of stock.

DON'T BUY

It is at a new high in terms of price but not new highs in terms of Price/Book. There is no yield and a 25% downside risk.

BUY

It is a leader in the field so the price is at a premium for a good reason. Has had a good bounce. You could also look at MedTech and Thermo-Fisher.

TOP PICK

World's leader in med tech. He's doubling down on US healthcare. Leader in cardio surgical technology. Healthcare, neglected through Covid, will be a very high growth area for the next couple of years. No dividend. (Analysts’ price target is $49.96)

PARTIAL SELL

Can be a safe haven stock. Health care offers defence. But BSX has had a big run and he expects this market to roll over a bit. Take some profits and wait for opportunities, which could mean buying this back in 2-3 months. Has fantastic fundamentals, but valuation is rich.

BUY

Likes it very much. Higher growth. Under pressure post-earnings. Predominantly everything cardiovascular. Covid put off elective surgeries, and these are starting to return. For the rest of 2022, increased volume might offset inflationary pressures.

WAIT

She has owned it for many years and it has not done anything. The COVID scares cast shadows over medical procedure demand. As a medical device provider it has faced head winds. Demand should ramp back up, but it will take confidence by patients to return for procedures.

PAST TOP PICK

(A Top Pick Dec 01/20, Up 22%) Covid delayed surgeries. Labour shortages. Both are holding the stock back, but will improve. Solid, long-term core investment.

HOLD

Holds other healthcare plays. There is a good place for these names in portfolios. The organic growth from resuming treatment and surgeries will be interesting to follow. Wouldn't worry about the pullback.

WAIT

BSX vs. MDT Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.

BUY

Medical device maker. It has been a bit of a laggard. It was the market darling until 2019 and then they started to have a couple of misses and issues with products. He thinks these are all transient issues. He thinks in 2022 they will grow revenue in high single digits. He is going to stick with it and would buy it here.

Showing 16 to 30 of 74 entries

Most Recent Experts

Keith Richards

ValueTrend Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Campbell (2)

Stone Castle Investment Management Inc.

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)